Company Overview and News

 
Peru will likely create Pacific Ocean reserve in early 2019 -govt

2018-07-09 reuters
LIMA (Reuters) - Peruvian President Martin Vizcarra’s government is planning to create an ocean reserve in the first quarter to protect feeding and breeding grounds for humpback whales and other marine species, the environment minister said on Monday.
KAR KRNGY KRNGF

 
PXP Energy trims Q1 net loss

2018-05-10 bworldonline
PXP Energy Corp. trimmed its losses to P3.7 million in the first quarter, the company said on Thursday, in part because of higher petroleum revenues resulting from an improvement in the price of crude oil during the period.
KAR TLW KRNGY KRNGF

 
[Press] Tullow Oil: AGM Trading Update

2018-04-25 oilvoice
25 April 2018 – Tullow Oil plc (Tullow) issues the following Trading Update for the period 1 January to 25 April 2018. This statement is issued in advance of the Group's Annual General Meeting (AGM) which is being held at Tullow Oil plc, Building 9 Chiswick Park, London, W4 5XT at 12pm today. The Group will announce its Trading Statement and Operational Update on 27 June 2018 and Half Year Results will be announced on 25 July 2018.
KAR TLW KRNGY KRNGF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:KAR / KAROON GAS AUSTRALIA LIMITED on message board site Silicon Investor.

Hewlett-Packard (HPQ) Hewlett-Packard (HPQ) Hewlett-Packard (HPQ) Hewlett Packard Enterprise (HPE) Hewlett Packard Enterprise (HPE) Hewlett Packard Enterprise (HPE)
HWP -- Hewlett Packard HWP -- Hewlett Packard HWP -- Hewlett Packard Transkaryotic(tktx) Transkaryotic(tktx) Transkaryotic(tktx)
ENVK - Envirokare Tech Inc. ENVK - Envirokare Tech Inc. ENVK - Envirokare Tech Inc. Karl Rove: A mastermind or a liability for George Bush Karl Rove: A mastermind or a liability for George Bush Karl Rove: A mastermind or a liability for George Bush
Martial Arts, Karate Martial Arts, Karate Martial Arts, Karate KARATE MOVIE STARS VS. BASHERS ! who would win? KARATE MOVIE STARS VS. BASHERS ! who would win? KARATE MOVIE STARS VS. BASHERS ! who would win?
Karma is as Karma Does Karma is as Karma Does Karma is as Karma Does PBSC - Packard BioScience PBSC - Packard BioScience PBSC - Packard BioScience